Health News Releases

17:15

Rigaku opens Rigaku Technology Center Taiwan

Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a ne

15:55

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and ph

15:15

Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation

Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award (https://baszuckigroup.com/metabolic-psychiatry-scholar-award/), a new initiative that suppo

14:50

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54343084&newsitemid=20251021006409&lan=en-US&anchor=TSE%3A4502%2FNYSE%

11:10

IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation

IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and le

October 21, 09:45

Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors

Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entere

October 20, 15:07

Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO

Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth f

October 19, 16:02

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimul

October 17, 14:50

HistoSonics Announces Oversubscribed $250 Million Growth Financing

HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new owners

October 17, 14:15

New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, today, celebrates the grand opening of its dedicated Health & Pharm

October 16, 16:15

SS&C Technologies Completes Acquisition of Calastone

SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2025-Enterprise-Press-Release-1025%26utm_medium%3Dpressreleas

October 15, 11:45

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54337814&newsitemid=20251013125479&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5

October 14, 11:40

Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent

Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54336442&newsitemid=20251009983648&lan=en-US&anchor=Parse+Biosciences&index=1&md

October 12, 13:00

Heidi Secures $65 Million USD in Series B Funding to Accelerate Building an AI Care Partner for Every Clinician

Heidi (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heidihealth.com%2F&esheet=54334156&newsitemid=20251005012225&lan=en-US&anchor=Heidi&index=1&md5=660ced366440a0565290ef7747c

October 12, 11:00

Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)

Mundipharma today announced completion of patient enrolment for the ongoing, global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin). The ReSPECT trial is a global, randomised, double-blind

October 12, 10:30

Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI

Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world’s #1 AI CRM, today announced that Haleon will leverage Salesforce

October 10, 17:20

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study

Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept s

October 10, 16:55

Tempus Joins Parse Biosciences’ Certified Service Provider Network

Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54333556&newsitemid=20251008146500&lan=en-US&anchor=Parse+Biosciences&index=1&md5

October 10, 14:40

In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones

Masimo (https://www.masimo.com/) (NASDAQ: MASI) today announced the findings of an exploratory analysis for a unique feasibility study published in CHEST Critical Care in which Dr. Andrew Goodwin and

October 10, 11:10

TCG Crossover (“TCGX”) Announces Oversubscribed $1.3B TCGX Fund III

TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors an

October 05, 11:55

Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments

Kinaxis® (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54333058&newsitemid=20251002088321&lan=en-US&anchor=Kinaxis%26%23174%3B&index=1&md5=bc238f272987

October 05, 11:40

Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair

Neuraptive Therapeutics, Inc., a biotechnology company focused on developing novel therapies to improve outcomes in peripheral nerve injuries (PNI), today announced the first patient has been enrolled

October 02, 14:50

WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

WHOOP (https://www.whoop.com/kr/en/), the human performance company, today announced the launch of WHOOP Advanced Labs (https://www.whoop.com/kr/en/advanced-labs/), a groundbreaking new feature that c